Truist Securities Starts Dianthus Therapeutics (DNTH) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Guggenheim on Dianthus (DNTH) and Leads BioLabs Deal: 'We view this as a well-structured deal'
October 16, 2025 9:56 AM EDTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $100.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).
The analyst comments "Today, DNTH announced an exclusive global (ex-Greater China) license agreement with Leads Biolabs (HKG: 9887) for DNTH-212, a first-in-class bifunctional BDCA2 and BAFF/APRIL inhibitor, designed to modulate both innate and... More
